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Short ArticleThe Atypical PKC-Interacting
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blasts and osteoclasts, respectively. Pathological bone
resorption is produced when this balance is tilted toward
an increased osteoclastic activity like in osteoporosis,
rheumatoid arthritis, or as a consequence of genetic
malfunctions such as in the Paget’s disease of the bone
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Once released from IB, NF-B enters the nucleus,
where it activates the transcription of a number of genesThe atypical PKCs (aPKCs) have been implicated ge-
coding for prosurvival and differentiation proteins andnetically in at least two independent signaling cas-
inflammatory cytokines. TRAF6 knockout (KO) micecades that control NF-B and cell polarity, through the
show impaired NF-B activation in IL-1-stimulated cellsinteraction with the adapters p62 and Par-6, respec-
and, interestingly, display an osteopetrotic phenotypetively. P62 binds TRAF6, which plays an essential role
(Kobayashi et al., 2001, 2003; Lomaga et al., 1999), whichin osteoclastogenesis and bone remodeling. Recently,
implicates this important adaptor not only in inflamma-p62 mutations have been shown to be the cause of
tion and innate immunity but also in bone remodeling.the 5q35-linked Paget’s disease of bone, a genetic
As p62 binds TRAF6 (Sanz et al., 2000) and mutationsdisorder characterized by aberrant osteoclastic activ-
in the p62 gene are the cause of the PDB (Hocking etity. Here we show that p62, like TRAF6, is upregulated
al., 2002; Laurin et al., 2002), it is possible that p62, likeduring RANK-L-induced osteoclastogenesis and that
TRAF6, may be involved in the regulation of osteoclastthe genetic inactivation of p62 in mice leads to im-
signaling, which is mainly controlled by the TNF familypaired osteoclastogenesis in vitro and in vivo, as well
cytokine RANK-L. This ligand binds its receptor RANK,as inhibition of IKK activation and NF-B nuclear trans-
activating a TRAF6-dependent mechanism to promotelocation. In addition, RANK-L stimulation leads to the
NF-B and Src activation (Wong et al., 1999), both play-inducible formation of a ternary complex involving
ing roles in osteoclast function (Franzoso et al., 1997;TRAF6, p62, and the aPKCs. These observations dem-
Iotsova et al., 1997; Soriano et al., 1991). Here we showonstrate that p62 is an important mediator during os-
that p62 is dramatically induced during osteoclastogen-teoclastogenesis and induced bone remodeling.
esis. The study of mice deficient for this gene reveals
that it plays an important role in osteoclast differentia-Introduction
tion and NF-B activation in response to RANK-L in vitro
Bone normal physiology relies on a finely tuned balance and in osteoclastogenesis in vivo in mice injected with
between formation and resorption controlled by osteo- the calciotropic hormone PTHrP. Therefore, our results
demonstrate that p62 is an important component in the
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disruption of the p62 gene (Figure 1C). The lack of ex-
pression of functional p62 was determined by immu-
noblotting of extracts from p62/ embryo fibroblasts
(Figure 1D).
Role of p62 in Bone Physiology
The p62 KO mice were born in Mendelian proportions
and were grossly normal. Six- to eight-week-old p62 KO
mice did not show any sign of osteopetrosis. Radio-
grams of the whole bodies did not display obvious differ-
ences between wild-type (wt) and p62 KO mice (data
not shown). Histological analysis of sections from long
bones (femurs and tibias) from the mutant mice revealed
similar cortical thickness as compared to wt, and no
alterations were found in the trabecular size and distri-
bution or in the number of osteoclasts (Figure 2A). This
suggests that basal osteoclastogenesis is not affected
by the loss of p62. However, it is possible that osteoclast
normal physiology in vivo under conditions in which
bones are challenged by osteoclastogenic stimuli such
as the calciotropic hormone PTHrP, which induces
osteoclastogenesis by means of the RANK-L pathway
(Li et al., 2000), may be impaired in the p62 KO mice.
To address this possibility, wt and p62-deficient mice
were intraperitoneally injected with 20 g of recombi-
nant PTHrP per day during 4 days. Afterward, mice were
sacrificed, and bone osteoclastogenic activity was de-
termined by histological analysis. Serum was also ob-
tained from these mice, and IL-6 levels were measured
by ELISA. Interestingly, the number of TRAP osteo-Figure 1. p62 Induction and Gene Targeting at the p62 Locus
clasts below the growth plate in the tibias of PTHrP-(A) BMDMs were stimulated with M-CSF or M-CSF plus RANK-L for
injected KO mice was severely reduced as compareddifferent times, after which cell extracts were prepared and p62
to that of wt controls (Figure 2B). Thus, whereas thelevels determined by immunoblotting. These are representative ex-
periments of another three with similar results. PTHrP-injected wt mice show 40 	 5 osteoclasts/mm2,
(B) Restriction map of the p62 locus (p62 wt); the targeting vector identically treated KO mice only show 19 	 3 osteo-
was integrated into the endogenous locus by homologous recombi- clasts/mm2. The sham-treated wt mice show 6 	 2 os-
nation and gave rise to the mutant allele (p62 Mutant). The boxes
teoclasts/mm2, similar to what is detected in identicallyindicate exons.
treated KO mice (5 	 2 osteoclasts/mm2). Of note, the(C) Southern blot analysis of litters derived from heterozygote in-
bone volume (BV/TV) of KO mice is slightly increasedtercross (/, wt; / homozygous).
(D) Immunoblot analysis of extracts from EFs wt (/) or p62 defi- as compared with wt mice (tibia wt 12.1 	 1.5 versus
cient (/). tibia KO 13.9 	 2.7; femur wt 10.2 	 0.8 versus femur
KO 12.8 	 1.1). Consistently, there was a small increase
in the trabecular number (TbN) in the p62 mutant mice
as compared to wt mice (tibia wt 3.5 	 0.3 versus tibia
Results and Discussion KO 4.0 	 0.4; femur wt 3.6 	 0.3 versus femur KO 4.9 	
0.5). Also, the trabecular separation (TbSp) was slightly
Induction of p62 and Generation of p62/ Mice reduced in the mutant mice (tibia wt 259 	 26 versus
In order to determine the potential physiological role of tibia KO 223 	 28; femur wt 258 	 23 versus femur KO
p62, we initially incubated bone marrow-derived macro- 183 	 21).
phages (BMDMs) from wild-type mice with M-CSF and
RANK-L for different times, after which cell extracts were
prepared and the expression of p62 was analyzed. Inter- Important Role of p62 in Osteoclastogenesis
In Vitroestingly, a detectable increase in p62 levels was ob-
served as early as 2 hr after RANK-L addition, but a In good agreement with the TRAP data, IL-6 production
in response to PTHrP injection is reduced in the p62much more dramatic rise was seen at day 1, whereas
p62 levels remained elevated at days 4 and 6. To further KO mice (Figure 2C). IL-6 synthesis in this experimental
setting is produced as a consequence of activated os-analyze the role of this adaptor protein in vivo, we geneti-
cally inactivated the p62 gene in mice by homologous teoclasts that respond to the RANK-L generated by os-
teoblasts and other stromal cells stimulated by PTHrPrecombination (Figure 1B). Mice heterozygous for the
p62-disrupted allele were intercrossed to generate ho- (Lee and Lorenzo, 1999). As PTHrP-induced serum
RANK-L levels in p62 KO mice were indistinguishablemozygous mutant KO mice. Southern blot analysis of
genomic DNA isolated from tails revealed successful from those in wt mice (data not shown), it can be inferred
p62 in RANK-Activated Osteoclastogenesis
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Figure 2. PTHrP-Induced Osteoclastogen-
esis Is Impaired in p62-Deficient Mice
(A) Hematoxylin-eosin-stained sections of
tibias from untreated wt and p62 KO mice
show normal bone morphology and basal os-
teoclastogenesis. (B) TRAP staining on sec-
tions of tibias from wt and p62 KO mice chal-
lenged with PTHrP. A significant reduction in
the osteoclastogenic response to the PTHrP
injection was observed in p62-deficient mice.
(C) Serum IL-6 levels induced by PTHrP are
impaired in the p62 KO mice. These are repre-
sentative experiments of another three with
similar results.
that p62 is a critical intermediary in RANK signal trans- indicating the specificity of the NFATc1 effects and that
p62 does not control TRAF6 synthesis. As p62 bindsduction in vivo. To determine whether the loss of p62
would affect osteoclast differentiation in vitro, BMDMs, PKC, which has been shown genetically to control
NF-B (Duran et al., 2003; Leitges et al., 2001), we nexteither wt or p62/, were incubated with M-CSF and
RANK-L for 6 days, after which TRAP-positive multinu- determined whether this aPKC is also involved in osteo-
clastogenesis. Results of Figure 3 (3A, lower panel; 3B,cleated osteoclasts were identified. Wild-type BMDMS
gave a robust osteoclastogenic response, which was right panel; and 3C, right panel) demonstrate that the
loss of PKC does not inhibit (but even seems to favor)dramatically inhibited in p62-deficient cultures (Figure
3A, upper panel, and 3B, left panel). These results indi- osteoclast formation or NFTAc1 production. Therefore,
p62 actions in this cellular system appear to be PKC in-cate that p62 is required for an optimal induced osteo-
clastogenesis in vitro and in vivo. The synthesis of the dependent.
transcription factor NFATc1 is potently induced during,
and is required for, osteoclastogenesis (Takayanagi et NF-B Signaling in p62-Deficient Osteoclasts
Previous results from our and other laboratories haveal., 2002). To investigate whether the loss of p62 impacts
NFATc1 synthesis in this system, BMDMs were incu- suggested that p62 is necessary for NF-B activation
by linking TRAF6 to IKK stimulation (Sanz et al., 2000).bated as above for different times, after which cell
extracts were analyzed by immunoblotting with anti- Interestingly, although the early RANK-L-stimulated ac-
tivation of NF-B in BMDMs is not inhibited in the p62NFATc1 antibody. The data of Figure 3C (left panel) show
that RANK-L induced NFATc1 synthesis in BMDMs wt KO cells (Figure 4A, left panel), which is consistent with
the fact that p62 is nearly undetectable in cultures thatcultures but that this is dramatically reduced in p62-
deficient cells, consistent with the data from the osteo- have not been exposed to RANK-L for a relatively long
period of time, at 24 hr and 48 hr of RANK-L stimulation,clastogenesis experiments. As a control, induced TRAF6
protein levels produced by RANK-L in the same cultures NF-B activation requires p62 (Figure 4A, right panel).
This requirement is maintained even at 6 days of cultureis not affected by the loss of p62 (Figure 3C, left panel),
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Figure 3. p62/ but Not PKC/ Mice Have Defective RANK-L-Mediated Osteoclastogenesis In Vitro
BMDMs from either wt, p62, or PKC KO mice (A) were incubated with M-CSF plus RANK-L for 6 days, after which the number of TRAP
multinucleated cells was determined. (B) Quantitation of TRAP multinucleated cells in cultures of the above experiments. Results are the
mean 	 SD of three independent experiments with incubations in duplicate. (C) (Left panel) BMDMs from wt or p62 KO mice were stimulated
with RANK-L for 24 or 48 hr, and the induction of NFTAc1 and TRAF6 was determined by immunoblotting. (Right panel) BMDMs as above
were incubated with M-CSF plus RANK-L for 6 days, after which NFATc1 levels were determined as above. These are representative experiments
of another three with similar results.
p62 in RANK-Activated Osteoclastogenesis
307
promotes the p62-aPKC interaction. Therefore, cell ex-
tracts from the above experiment were immunoprecipi-
tated with anti-p62 antibody and immunoblotted with
an anti-aPKC antibody. There is a basal association
of aPKC with p62 in unstimulated RAW cells that is
dramatically induced upon RANK-L addition (Figure 4C,
right panel). In addition, in primary BMDMs incubated
in the presence of RANK-L as in Figure 4B, a specific
association of p62 with TRAF6 and aPKC is readily de-
tectable (Figure 4D). These results indicate that the acti-
vation of the RANK pathway promotes the formation of
a TRAF6-p62-aPKC complex required for NF-B activa-
tion, NFATc1 synthesis, and osteoclast differentiation.
As the PKC/ BMDMs do not have osteoclastogenic
defects, collectively these results suggest that /PKC
may be the aPKC involved in this pathway. The /PKC
KO is embryonic lethal at very early stages (M.T.D.-M.
and J.M., unpublished data) precluding any analysis of
osteoclasts. Further studies using conditional KOs when
available will make this analysis possible.
The signaling pathways that regulate osteoclast phys-
iology are becoming increasingly investigated because
of the great impact that alterations in bone remodeling
have in human diseases. Our data identify p62 as a
player in this pathway. The fact that induced but not
basal osteoclastogenesis is affected by the loss of p62
is reminiscent of the NIK/ mice phenotype (Novack et
al., 2003). NIK activates a novel noncanonical NF-B
pathway that is initiated by the phosphorylation and
Figure 4. Role of p62 in RANK-L Signaling in Osteoclasts
processing of p100 (NF-B2) to give p52/RelB com-
(A) (Left panel) BMDMs from wt and p62 KO mice were stimulated
plexes (Moscat et al., 2003). However, this non-canoni-with RANK-L for 15 and 30 min, after which nuclear extracts were
cal pathway does not appear to be affected in the p62prepared and analyzed by EMSA for nuclear NF-B binding activity.
(Right panel) BMDMs as above were stimulated with RANK-L for 1 KO (data not shown), which suggests that both are inde-
and 2 days, after which nuclear NF-B binding activity was deter- pendent but important cascades for bone remodeling
mined. (B) In another set of experiments, BMDMs were incubated during induced conditions. Recent data revealed that in
with RANK-L for 6 days, after which extracts were prepared for
fos/ mice, bone remodeling and erosion during rheu-nuclear NF-B activity (left panel) or immunoprecipitated with an
matoid arthritis are mediated by osteoclasts (Redlich etanti-IKK
 antibody and the IKK enzymatic activity was determined.
al., 2002). It is tempting to speculate that, as p62 is(C) RAW cells were stimulated with RANK-L for 10 min and extracts
were immunoprecipitated either with anti-TRAF6 or anti-p62, after important during induced but not basal osteoclastogen-
which the associated p62 or aPKC, respectively, was detected by esis, its inhibition may be beneficial for the treatment of
immunoblottting with specific antibodies. (D) Extracts from BMDMs rheumatoid arthritis with, in principle, relatively minor
incubated as in (B) were immunoprecipitated as above. These are
toxic effects in bone basal physiology. On the other hand,representative experiments of another three with similar results.
it is interesting to note that the osteoclasts in the pagetic
lesions are hyperactivated (Roodman, 1996), which, com-
bined with the data shown here clearly demonstrating that
(Figure 4B, left panel), consistent with the p62 induction
p62 is necessary for osteoclastogenesis, suggests thatkinetic (Figure 1A). The action of p62 in this pathway is
the pagetic mutations in p62 lead to a permanentlymost likely at the level of IKK, since this activity is se-
active protein. In fact, in bone resorption assays, theverely inhibited in p62 KO osteoclasts (Figure 4B,
activity of p62 KO osteoclastic cultures is much moreright panel).
reduced than that of parallel wt cultures (data not
shown). In connection with this, the ectopic expression
of a p62 construct harboring a pagetic mutation is moreTRAF6-p62-aPKC Complex Formation
efficient in activating NF-B than the expression of ain Response to RANK-L
wt construct (see Supplemental Figure S1 at http://We next sought to determine whether TRAF6 and p62
www.developmentalcell.com/cgi/content/full/6/2/interact in response to the stimulation with RANK-L.
303/DC1). The precise mechanism whereby the PDBThus, the preosteoclast cell line RAW 264.7 (RAW) was
mutations affect p62 function is unclear yet, but thetreated with RANK-L, cell extracts were prepared and
observation that IL-6 synthesis is severely reduced inTRAF6 was immunoprecipitated, and the associated
the p62 KO mice is consistent with the fact that IL-6p62 was detected by immunoblotting. Results of Figure
levels are elevated in pagetic patients, which is respon-4C (left panel) show that RANK-L triggers the formation
sible, at least in part, for the osteoclastic pagetic pheno-of a p62-TRAF6 complex. As p62 is a scaffold for the
aPKCs, we next determined whether RANK activation type (Roodman, 1996).
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Experimental Procedures IKK activity was determined in anti-IKK
 immunoprecipitates as
described (Lallena et al., 1999).
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